TreatmentTrends®: Advanced/Metastatic Breast Cancer (U.S.) examines the current trends in the management of advanced/metastatic breast cancer in the United States from the perspective of surveyed medical oncologists.
This report series provides the opportunity to gain greater understanding of medical practice patterns in breast cancer by disease setting, physicians’ perceptions of brands and specific product attributes, and the impact of sales and messaging efforts.
Sample Frame & Methodology:
100 medical oncologists complete a 60-minute online quantitative survey with several open-ended questions for qualitative feedback.
To qualify, respondents must meet the following criteria:
- Minimum of 25 Breast cancer patients under management per month
- Have been in practice a minimum of 2 years and a maximum of 30 years
- More than 75 percent of professional time spent in clinical practice (academic hospital setting allowed 50 percent practice time)
- Final report in PowerPoint format
- Access to author
Key Drugs Covered:
Herceptin, Perjeta, Kadcyla, Tykerb, Abraxane, paclitaxel, docetaxel, Xeloda, Afinitor, anastrozole, letro-zole, exemestane, Faslodex
LaunchTrends®: Perjeta and Kadcyla (US)
Pharmacor®: Breast Cancer
DecisionBase®: Breast Cancer (Advanced/metastatic HR+/HER2-)
PatientBase®: Breast Cancer in G7, Brazil, Russia, India, China, Mexico, Turkey, and South Korea
Physician and Payer Forum® (Emerging Markets): Breast Cancer in Chi-na and South Korea: Physician and Payer Insight into Market Access Drivers
Physician and Payer Forum® (EU5): Tightening Healthcare Budgets and Elevated Cost-Effectiveness Expectations: How Will Payers and Prescrib-ers Proiritize Targeted Agents for Breast Cancer in the EU5?